Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EXAS 
EXACT Sciences Corporation (EXAS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: EXAS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $68.46
1 Year Target Price $68.46
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.42% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.24B USD | Price to earnings Ratio - | 1Y Target Price 68.46 |
Price to earnings Ratio - | 1Y Target Price 68.46 | ||
Volume (30-day avg) 26 | Beta 0.98 | 52 Weeks Range 39.97 - 72.83 | Updated Date 07/14/2025 |
52 Weeks Range 39.97 - 72.83 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.06% | Operating Margin (TTM) -11.53% |
Management Effectiveness
Return on Assets (TTM) -1.83% | Return on Equity (TTM) -36.89% |
Valuation
Trailing PE - | Forward PE 2500 | Enterprise Value 11527290605 | Price to Sales(TTM) 3.62 |
Enterprise Value 11527290605 | Price to Sales(TTM) 3.62 | ||
Enterprise Value to Revenue 4.08 | Enterprise Value to EBITDA 215.11 | Shares Outstanding 188638000 | Shares Floating 186787137 |
Shares Outstanding 188638000 | Shares Floating 186787137 | ||
Percent Insiders 0.92 | Percent Institutions 98.49 |
Upturn AI SWOT
EXACT Sciences Corporation
Company Overview
History and Background
EXACT Sciences Corporation was founded in 1995. Initially focused on DNA-based diagnostics for cancer, it gained prominence with the development and commercialization of Cologuard, a noninvasive colon cancer screening test. The company has expanded through organic growth and acquisitions to offer a broader range of cancer diagnostics.
Core Business Areas
- Screening: Focuses on early detection of colorectal cancer through Cologuard and related services.
- Precision Oncology: Provides genomic testing services to guide cancer treatment decisions, including Oncotype DX.
- COVID-19 Testing: Offered COVID-19 testing services during the pandemic; this segment is decreasing in significance.
Leadership and Structure
Kevin Conroy is the Chairman and CEO. The company has a standard corporate structure with departments for R&D, marketing, sales, operations, and finance. A Board of Directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Cologuard: A noninvasive stool DNA screening test for colorectal cancer. It is the company's primary revenue driver. Exact Sciences estimates it has ~40% market share of the non-invasive colorectal cancer screening market. Competitors include colonoscopies, fecal immunochemical tests (FIT), and other stool DNA tests (e.g., from Freenome, Guardant Health).
- Oncotype DX: A suite of genomic tests that analyze tumor samples to predict the likelihood of cancer recurrence and response to chemotherapy. Competitors include Genomic Health, Foundation Medicine and other diagnostic testing companies.
Market Dynamics
Industry Overview
The cancer diagnostics market is growing rapidly, driven by increasing cancer incidence, advancements in genomic technologies, and a focus on early detection and personalized medicine. Key trends include liquid biopsies, multi-cancer early detection (MCED) tests, and the integration of AI and machine learning.
Positioning
EXACT Sciences is a leading player in the noninvasive colorectal cancer screening market with Cologuard. It also holds a strong position in the genomic testing market with Oncotype DX. The company is focused on expanding its product portfolio and market reach through strategic acquisitions and partnerships.
Total Addressable Market (TAM)
The TAM for cancer diagnostics is estimated to be tens of billions of dollars globally. EXACT Sciences is targeting various segments of this market, including colorectal cancer screening, other gastrointestinal cancers, and multi-cancer early detection (MCED). Their TAM includes both screening markets and precision oncology.
Upturn SWOT Analysis
Strengths
- Strong brand recognition with Cologuard
- Established market presence in colorectal cancer screening
- Proprietary technology and intellectual property
- Experienced management team
- Direct-to-consumer marketing capabilities
Weaknesses
- Reliance on a single primary product (Cologuard)
- High marketing and sales expenses
- Reimbursement risks from payers
- Competition from established screening methods like colonoscopy
- Profitability concerns
Opportunities
- Expansion into new cancer screening markets (e.g., liver, esophageal)
- Development of multi-cancer early detection (MCED) tests
- Strategic partnerships with healthcare providers and payers
- International expansion
- Technological advancements in liquid biopsies and genomic testing
Threats
- Increased competition from other diagnostic companies
- Changes in healthcare regulations and reimbursement policies
- Adverse clinical trial results
- Economic downturn affecting healthcare spending
- Technological disruption from new diagnostic methods
Competitors and Market Share
Key Competitors
- GILD
- DGX
- LH
- FGEN
Competitive Landscape
EXACT Sciences has a strong position in the noninvasive colorectal cancer screening market, but faces increasing competition from established players and new entrants. The company's success depends on its ability to innovate, expand its product portfolio, and effectively market its products.
Major Acquisitions
PreventionGenetics
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: Expanded the company's genetic testing portfolio and capabilities.
Thrive Earlier Detection Corp.
- Year: 2021
- Acquisition Price (USD millions): 2150
- Strategic Rationale: To accelerate the development and commercialization of a multi-cancer early detection (MCED) test.
Growth Trajectory and Initiatives
Historical Growth: EXACT Sciences has experienced significant revenue growth driven by increasing Cologuard adoption and acquisitions. However, profitability remains a challenge.
Future Projections: Analyst estimates for future growth vary depending on factors such as market penetration, competition, and regulatory approvals. Analysts on average have a BUY rating.
Recent Initiatives: Recent initiatives include expanding the Cologuard sales force, investing in R&D for new diagnostic tests, and pursuing strategic acquisitions and partnerships.
Summary
EXACT Sciences is a leading diagnostics company, particularly known for its Cologuard test. The company has grown significantly through innovation and acquisitions, but profitability remains a challenge. While Cologuard dominates the noninvasive colorectal cancer screening market, competition is increasing. Future success hinges on expanding its product portfolio and managing costs effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Materials
- Third-party Market Research Reports
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EXACT Sciences Corporation
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2001-02-01 | Chairman of the Board & CEO Mr. Kevin T. Conroy J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 6900 | Website https://www.exactsciences.com |
Full time employees 6900 | Website https://www.exactsciences.com | ||
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.